- Home
- DSGN vs FLC Comparison
DSGN vs FLC Comparison
Compare DSGN & FLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- FLC
- Stock Information
- Founded
- DSGN 2017
- FLC 2003
- Country
- DSGN United States
- FLC United States
- Employees
- DSGN N/A
- FLC N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- FLC Trusts Except Educational Religious and Charitable
- Sector
- DSGN Health Care
- FLC Finance
- Exchange
- DSGN Nasdaq
- FLC Nasdaq
- Market Cap
- DSGN 208.9M
- FLC 174.2M
- IPO Year
- DSGN 2021
- FLC N/A
- Fundamental
- Price
- DSGN $5.85
- FLC $17.78
- Analyst Decision
- DSGN
- FLC
- Analyst Count
- DSGN 0
- FLC 0
- Target Price
- DSGN N/A
- FLC N/A
- AVG Volume (30 Days)
- DSGN 167.2K
- FLC 37.8K
- Earning Date
- DSGN 11-06-2025
- FLC 01-01-0001
- Dividend Yield
- DSGN N/A
- FLC 6.64%
- EPS Growth
- DSGN N/A
- FLC N/A
- EPS
- DSGN N/A
- FLC N/A
- Revenue
- DSGN N/A
- FLC N/A
- Revenue This Year
- DSGN N/A
- FLC N/A
- Revenue Next Year
- DSGN N/A
- FLC N/A
- P/E Ratio
- DSGN N/A
- FLC N/A
- Revenue Growth
- DSGN N/A
- FLC N/A
- 52 Week Low
- DSGN $2.60
- FLC $12.62
- 52 Week High
- DSGN $7.77
- FLC $15.45
- Technical
- Relative Strength Index (RSI)
- DSGN 55.18
- FLC 83.75
- Support Level
- DSGN $5.65
- FLC $17.42
- Resistance Level
- DSGN $6.65
- FLC $17.25
- Average True Range (ATR)
- DSGN 0.49
- FLC 0.09
- MACD
- DSGN -0.05
- FLC 0.04
- Stochastic Oscillator
- DSGN 50.40
- FLC 98.39
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.